



Increased DNA methylation variability in type 1 diabetes across three immune effector cell types

Dirk S. Paul^{1,2,22,*}, Andrew E. Teschendorff^{3,4,22}, Mary A. N. Dang^{5,22}, Robert Lowe^{5,22}, Mohammed I. Hawa⁵, Simone Ecker¹, Stephanie Cunningham⁵, Alexandra R. Fouts⁶, Anita Ramelius⁷, Frances Burden^{8,9}, Samantha Farrow^{8,9}, Sophia Rowston^{8,9}, Karola Rehnstrom^{8,9}, Mattia Frontini^{8,9,10}, Kate Downes^{8,9}, Stephan Busche^{11,12}, Warren Cheung^{11,12}, Bing Ge^{11,12}, Marie-Michelle Simon^{11,12}, David Bujold^{11,12}, Tony Kwan^{11,12}, Guillaume Bourque^{11,12}, Avik Datta¹³, Ernesto Lowy¹³, Laura Clarke¹³, Paul Flicek¹³, Emanuele Libertini¹, Simon Heath¹⁴, Marta Gut¹⁴, Ivo G. Gut¹⁴, Willem H. Ouwehand^{8,9,10,15}, Tomi Pastinen^{11,12}, Nicole Soranzo^{8,15}, Sabine E. Hofer¹⁶, Beate Karges^{17,18}, Thomas Meissner^{18,19}, Bernhard O. Boehm^{20,21}, Corrado Cilio⁷, Helena Elding Larsson⁷, Åke Lernmark⁷, Andrea K. Steck⁶, Vardhman K. Rakyan^{5,22}, Stephan Beck^{1,22} & R. David Leslie^{5,22}

¹Medical Genomics, UCL Cancer Institute, University College London, London WC1E 6BT, UK; ²Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK; ³CAS Key Lab of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, China; ⁴Statistical Cancer Genomics, UCL Cancer Institute, University College London, London WC1E 6BT, UK; ⁵The Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK; ⁶Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO 80045, USA; ⁷Department of Clinical Sciences, Lund University, Skåne University Hospital SUS, Malmö, Sweden; ⁸Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0PT, UK; ⁹National Health Service (NHS) Blood and Transplant, Cambridge Biomedical Campus, Cambridge CB2 0PT, UK; ¹⁰British Heart Foundation Centre of Excellence, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; ¹¹Department of Human Genetics, McGill University, Montreal, Québec, H3A 0G1, Canada; ¹²McGill University and Genome Quebec Innovation Centre, Montreal, Québec, H3A 0G1, Canada; ¹³Vertebrate Genomics, EMBL-European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK; ¹⁴Centro Nacional de Análisis Genómico (CNAG), Parc Científic de Barcelona, Barcelona, Spain; ¹⁵Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB13 1SA, UK; ¹⁶Department of Pediatrics, Medical University of Innsbruck, 6020 Innsbruck, Austria; ¹⁷Division of Endocrinology and Diabetes, RWTH Aachen University, 52074 Aachen, Germany; ¹⁸German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany; ¹⁹Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich Heine University of Düsseldorf, 40225 Düsseldorf, Germany; ²⁰Division of Endocrinology, Department of Internal Medicine I, Ulm University Medical Centre, 89081 Ulm, Germany; ²¹Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 636921; Imperial College London, London SW7 2AZ, UK; ²²These authors contributed equally to this work.

*Contact: dsp35@medschl.cam.ac.uk

Abstract

The incidence of type 1 diabetes (T1D) has substantially increased over the past decade, suggesting a role for non-genetic factors such as epigenetic mechanisms in disease development. We performed an epigenome-wide association study across 406,365 CpGs in 52 monozygotic twin pairs discordant for T1D in three immune effector cell types: CD4⁺ T cells, CD19⁺ B cells, and CD14⁺CD16⁻ monocytes. We observed a substantial enrichment of differentially variable CpG positions (DVPs) in T1D twins compared to their healthy co-twins across all cell types. These T1D-associated DVPs were found to be reproducible and temporally stable, and to act independently of genetic variation. Evidence from cord blood of newborns who progressed to overt T1D suggests that the DVPs likely emerged after birth. Integration with cell type-specific gene regulatory circuits highlighted pathways involved in immune cell metabolism and cell cycle. Our findings, supported by 772 methylomes, implicate epigenetic changes in T1D that may contribute to disease pathogenesis.